DIAGENS-B(02526): Upgraded iMedLoop Platform Launches Globally and Opens API Subscriptions

date
17:03 19/11/2026
avatar
GMT Eight
DIAGENS-B(02526) announced that the upgraded version of iMedLoop (the Platform), the Group's medical imaging model development, research, and analysis platform, was officially launched at 9:00 a.m. Eastern Time on November 18, 2026 (www.imedloop.com). The Group is simultaneously opening API subscriptions globally.
DIAGENS-B(02526) announced that the upgraded version of its medical imaging model development, research and analysis platform iMedLoop (the "Platform") was officially launched at 9:00 a.m. Eastern Time on November 18, 2026 (www.imedloop.com). The Group has simultaneously opened API subscriptions globally. The core of this upgrade is the integration of the Group's sixth-generation medical imaging foundation model iMedImage 6.0 (iMed-6.0), expanding imaging analysis capabilities to a broad user base. Users may select specialty models offered by the Platform, or use the Platform to train, evaluate and deploy custom specialty models without writing code. Professional users can utilize Platform tools to organize and analyze imaging data, and can also invoke model capabilities within their own research systems through API subscriptions. Users can independently select specialty models provided by the Platform or developed themselves, upload various medical images or examination reports, and obtain interpretations presented in plain language, as a reference for understanding imaging findings and discussing examination results with physicians. The Group has accumulated a medical imaging dataset of more than 1.1 billion images, covering 19 imaging modalities. iMed-6.0 was trained on this massive dataset and possesses capabilities including three-dimensional localization of anatomical structures, lesion measurement and dynamic imaging analysis. The Board believes that the global launch of the upgraded Platform and the simultaneous opening of API subscriptions represent an important step for the Group in upgrading its business model and expanding into international markets. Building on its accumulated R&D and institutional service experience, the Group provides services to overseas medical institutions, research teams, independent researchers and developers through the Platform. Online Platform services and API subscriptions complement existing institutional model licensing and localized delivery, helping the Group expand its customer base and revenue sources. The Board believes that extending intelligent imaging interpretation services to more groups will help people around the world better understand examination results and more proactively manage their own health. The Group hopes that through iMedLoop, medical artificial intelligence will benefit more people globally and drive health management into a new era of intelligence.